You just read:

ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy

News provided by

Regeneron Pharmaceuticals, Inc.

Feb 28, 2011, 07:30 ET